Abstract:The study objective was to observe the treatment effect of the farnesoid X receptor (FXR) agonist GW4064 in a rat model of hilar cholangiocarcinoma to explore a new therapeutic target for gene therapy for hilar cholangiocarcinoma. Eighty male Wistar rats were randomly divided into four groups (treatment group, model group, control group and sham operation group, 20 rats in each group). The four groups were fed a standard diet. The treatment group and the model group were injected with a suspension of cholangiocarcinoma QBC939 cells into the hilar bile duct with a microsyringe, the control group was injected with normal saline, and the sham operation group was not injected with anything. A modified tail suspension test (TST) was used to evaluate the vitality of the rats. At 4 weeks, one rat in the treatment group and model group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at 6 weeks. After 6 weeks, hilar cholangiocarcinoma occurred in the treatment group and model group. Then, the treatment group was injected with GW4064 intraperitoneally at a dose of 50 mg/kg/day. One week after injection, the rats in the four groups were euthanized. Pathological examination confirmed that tumours had formed, and hilar bile duct tissues were taken from the four groups. FXR, Bsep, Ntcp and NF-κB expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After three weeks, the rats in the treatment group and model group ate less, and their weight was significantly reduced. Six weeks later, hilar cholangiocarcinoma was detected in the treatment group and model group. After treatment with GW4064, the ratios of FXR/GAPDH mRNA, Bsep/GAPDH mRNA, Ntcp/GAPDH mRNA and NF-κBp65/GAPDH mRNA were significantly different among the four groups. Under a light microscope, FXR protein reacted with anti-FXR antibody, Bsep protein reacted with anti-Bsep antibody, Ntcp protein reacted with anti-Ntcp antibody and NF-κBp65 protein reacted with anti-NF-κBp65 antibody, and they showed granular expression. Every pathological section included 4,800 cells, and there were different numbers of positive cells in each group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues. GW4064 increased the expression of FXR in tumour tissues. These findings suggest that FXR may be a new therapeutic target and that GW4064 may be helpful in the treatment of hilar cholangiocarcinoma.

Impact of Bile Acids on the Growth of Human Cholangiocarcinoma Via FXR

The Effect of FXR Agonist GW4064 on Growth of Human Cholangiocarcinoma Cell Line QBC939

Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway.

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats

Farnesiod X receptor expression in cholangiocarcinoma and in normal bile duct tissues

FXR Acts As a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.

Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma

FXR expression in rats of hilar cholangiocarcinoma

FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis

Promotion of Deoxycholic Acid Effect on Colonic Cancer Cell Lines In Vitro by Altering the Mucosal Microbiota

Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma

Effects of farnesoid X receptor on expression of fatty acid synthetase in HepG2 cells

Hepatocarcinogenesis in FXR−/− Mice Mimics Human HCC Progression That Operates Through HNF1α Regulation of FXR Expression

Intrabiliary RF Heat-Enhanced Local Chemotherapy of a Cholangiocarcinoma Cell Line: Monitoring with Dual-Modality Imaging--preclinical Study.

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction

Bile acids inhibit ferroptosis sensitivity through activating farnesoid X receptor in gastric cancer cells

Bile Acids Promote Gastric Intestinal Metaplasia By Upregulating Cdx2 And Muc2 Expression Via The Fxr/Nf-B Signalling Pathway

FXR Agonists Enhance the Sensitivity of Biliary Tract Cancer Cells to Cisplatin Via SHP Dependent Inhibition of Bcl-xL Expression

Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase

FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden

Farnesoid X receptor upregulates fibroblast growth factor 21 expression in cultured liver cells